Bioaccessibility and oral immunization efficacy of a chimeric protein vaccine against Ascaris suum

• Published in: Microbes and infection Vol. 25; no. 3; p. 105042
• Main Authors: Castro, Joseane C., Magalhães, Luisa MD, Almeida, Raquel M., Oliveira, Fabricio MS, Nogueira, Denise S., Gazzinelli-Guimarães, Ana Clara, Kraemer, Lucas, Barbosa, Fernando S., Santos, Flavianne Vieira, Minighin, Elaine C., Bueno, Lilian L., Bartholomeu, Daniella C., Labanca, Renata A., Fujiwara, Ricardo T.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-03-2023
• Subjects: Animals; Antigens, Helminth - genetics; Ascariasis - prevention & control; Ascaris; Ascaris suum; Humans; Immune response; Immunization; Mice; Mucous; Oral vaccine; Recombinant Fusion Proteins - genetics; Vaccines; Oral vaccine; Immune response; Mucous; Ascaris
• ISSN: 1286-4579; 1769-714X
• DOI: 10.1016/j.micinf.2022.105042

Human ascariasis has been characterized as the most prevalent neglected tropical disease worldwide. There is an urgent need for search to alternative prevention and control methods for ascariasis. Here we aimed to establish a protocol of oral immunization with a previously described chimera protein capable of resist through digestion and induce mucous protection against Ascaris suum infection. Mice were oral immunized with seven doses with one day interval and challenged with A. suum ten days after the last dose. In vitro digestion showed that 64% of chimeric protein was bioaccessible for absorption after digestion. Immunized mice display 66,2% reduction of larval burden in lungs compared to control group. In conclusion we demonstrated that oral immunization with chimera protein protects the host against A. suum larval migration leading to less pronounced histopathological lesions.
[Display omitted]